logo

Last Update

This profile was last updated on 7/26/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Bob Rappaport?

Bob A. Rappaport

Division Director of Anesthesia, Analgesia and Addiction Products

Food and Drug Administration

HQ Phone:  (301) 827-6500

Direct Phone: (301) ***-****direct phone

Email: r***@***.gov

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Food and Drug Administration

5600 Fishers Lane

Rockville, Maryland,20852

United States

Company Description

China's Food and Drug Administration (SFDA) is now offering a reward of about 50,000 US dollars for relevant information on counterfeit drug production. The bounty aims to "encourage the public to report illegal activities so as to determine, control and elimi...more

Background Information

Employment History

Director of the Division of Anesthesia, Analgesia and Rheumatology Products

Centers for Medicare and Medicaid Services


Affiliations

Cytogel Pharma LLC

Advisory Board Member


MMS Holdings Inc.

Scientific Advisor and Board Member


iX Biopharma Ltd

Scientific Advisor


ACTTION

Executive Committee


IMMPACT

Active Member of the Consensus Group


Centrexion Therapeutics Corporation

Clinical Advisory Board Member


Analgesic Concepts

Founder


Not Quite Heaven , CO.

Member


Jelsoft Enterprises Ltd.

Member


Quivive Pharma

Key Advisor


Education

M.D.


MD

The George Washington University School of Medicine and Health Sciences


Web References(192 Total References)


Is Post-Surgery Codeine a Risk for Kids?

www.elixirhealth.com [cached]

The agency is trying to determine if there have been other cases of accidental overdose or death in children taking codeine, and if there have been incidents like this when children have taken codeine after other kinds of surgical procedures, says Bob Rappaport, M.D., director of the Division of Anesthesia, Analgesia and Addiction Products (DAAAP) in FDA's Center for Drug Evaluation and Research.
There are a number of symptoms to watch for, says Rappaport. "The most important thing is that caregivers should tell the 911 operator or emergency department staff that their child has been taking codeine and is having breathing problems," Rappaport says.


Cytogel Pharma - Board of Managers & Advisory Board

cytogelpharma.com [cached]

Bob A. Rappaport, M.D.
Bob A. Rappaport, M.D., Dr. Rappaport joined the Cytogel Advisory Board as a Consultant in 2015, having retired from the FDA in October of 2014. Dr. Rappaport was Director of the Division of Anesthesia, Analgesia, and Addiction Products at the FDA for 12 years where he led a large team of physicians, scientists and regulatory project managers to oversee the investigation, development, approval, continued safety, and safe use of drug products to treat pain and addiction disorders, as well as drug products used in the setting of clinical anesthesia. He was an advocate for the development of novel analgesic, anesthetic and addiction drug products throughout his tenure, and instituted new standards for the study of these drugs. He has also been an active member of the IMMPACT consensus group since its inception. In 2010 he worked within FDA to build the ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks) public-private-partnership, which was initially designed to advance the field of analgesic drug development by improving analgesic clinical study design, conduct and analysis. This highly successful initiative was later expanded to include improving the study and development of anesthetics, and drugs to treat addiction and peripheral neuropathy. Dr. Rappaport was centrally involved with the FDA's continued efforts to encourage and assist in the development of abuse-deterrent opioid formulations, and with his staff he completed an updated guidance for the pharmaceutical industry on the development of analgesic drug products. In 2013, Dr. Rappaport received the Agency's Lifetime Achievement Award for his contributions to the anesthesia, analgesia, and addiction fields by accelerating the discovery and development of new drugs with improved efficacy and safety. Dr. Rappaport graduated from and completed his medical training at The George Washington University School of Medicine and Health Sciences, and is board certified in neurology and sleep medicine. In May of this year Dr. Rappaport will receive the 2015 John and Emma Bonica Public Service Award at the annual meeting of the American Pain Society.


Op Ed & Guest Columnists

www.snuscentral.org [cached]

Bob Rappaport (Director, Division of Anesthesia, Analgesia and Addiction Products, FDA Center for Drug Evaluation and Research)


drug abuse | MedNews

mednews.com [cached]

"Although this new formulation of OxyContin may provide only an incremental advantage over the current version of the drug, it is still a step in the right direction," said Bob Rappaport, M.D., director of the Division of Anesthesia and Analgesia Products in the FDA's Center for Drug Evaluation and Research.
"As with all opioids, safety is an important consideration," he said.


fda | MedNews

mednews.com [cached]

"Chantix has proven to be effective in smokers motivated to quit, but patients and health care professionals need the latest safety information to make an informed decision regarding whether or not to use this product," said Bob Rappaport, M.D., director of the FDA's Division of Anesthesia, Analgesia and Rheumatology Products.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory